---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-193906"
form_type: "8-K"
ticker: null
cik: "0001785173"
company_name: "89bio, Inc."
filed_at: "2024-08-05T23:59:59+00:00"
generated_at: "2026-05-31T13:11:49.181331+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# 89bio Q2 net loss $48M; appoints ex-CymaBay CSO Charles McWherter to board; Phase 3 MASH trials enrolling

## Summary
- Net loss $48.0M for Q2 2024 vs $38.4M YoY; R&D expenses rose to $44.9M.
- Cash, equivalents and marketable securities $531.4M as of June 30, 2024.
- Phase 3 ENLIGHTEN-Fibrosis (F2-F3 MASH) and ENLIGHTEN-Cirrhosis (F4) enrolling patients.
- Phase 3 ENTRUST (SHTG) topline data expected in 2025; enrollment ongoing.
- Charles McWherter, Ph.D., former CSO/President R&D of CymaBay (acquired by Gilead), appointed to Board of Directors.

## SEC filing metadata
- accession: 0001193125-24-193906
- form_type: 8-K
- cik: 0001785173
- company_name: 89bio, Inc.
- filed_at: 2024-08-05T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1785173/000119312524193906/0001193125-24-193906-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1785173/000119312524193906/d879198d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-193906
- JSON: https://secwatch.observer/filing/0001193125-24-193906.json
- Plain text: https://secwatch.observer/filing/0001193125-24-193906.txt

## Key facts
- Executive change
  Charles McWherter was appointed as member of the Board at 89bio, Inc..
  - Action: appointed
  - Role: member of the Board
  source text: On July 30, 2024, the board of directors (the “Board”) of the Company appointed Charles McWherter, Ph.D. as a member of the Board.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1785173/000119312524193906/0001193125-24-193906-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.